PHATHOM PHARMACEUTICALS INC (PHAT) Stock Price & Overview
NASDAQ:PHAT • US71722W1071
Current stock price
The current stock price of PHAT is 10.355 USD. Today PHAT is down by -0.14%. In the past month the price decreased by -13.73%. In the past year, price increased by 135.15%.
PHAT Key Statistics
- Market Cap
- 815.974M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.06
- Dividend Yield
- N/A
PHAT Stock Performance
PHAT Stock Chart
PHAT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PHAT. When comparing the yearly performance of all stocks, PHAT is one of the better performing stocks in the market, outperforming 93.12% of all stocks.
PHAT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHAT. Both the profitability and financial health of PHAT have multiple concerns.
PHAT Earnings
On February 26, 2026 PHAT reported an EPS of -0.29 and a revenue of 57.57M. The company beat EPS expectations (25.46% surprise) and missed revenue expectations (-1.06% surprise).
PHAT Forecast & Estimates
17 analysts have analysed PHAT and the average price target is 23.36 USD. This implies a price increase of 125.57% is expected in the next year compared to the current price of 10.355.
For the next year, analysts expect an EPS growth of 73.14% and a revenue growth 88.68% for PHAT
PHAT Groups
Sector & Classification
PHAT Financial Highlights
Over the last trailing twelve months PHAT reported a non-GAAP Earnings per Share(EPS) of -3.06. The EPS increased by 42.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.26% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PHAT Ownership
PHAT Latest News, Press Relases and Analysis
PHAT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.2 | 929.285B | ||
| JNJ | JOHNSON & JOHNSON | 20.8 | 582.039B | ||
| MRK | MERCK & CO. INC. | 22.24 | 285.833B | ||
| PFE | PFIZER INC | 8.9 | 151.141B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.43 | 120.315B | ||
| ZTS | ZOETIS INC | 16.73 | 48.807B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.334B | ||
| VTRS | VIATRIS INC | 5.38 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.22 | 11.405B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.983B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.157B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.94B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.56 | 4.046B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PHAT
Company Profile
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 371 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Company Info
IPO: 2019-10-25
PHATHOM PHARMACEUTICALS INC
100 Campus Drive, Suite 102
Florham Park NEW JERSEY 07932 US
CEO: Terrie Curran
Employees: 371
Phone: 13026365400
PHATHOM PHARMACEUTICALS INC / PHAT FAQ
What does PHAT do?
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 371 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
What is the stock price of PHATHOM PHARMACEUTICALS INC today?
The current stock price of PHAT is 10.355 USD. The price decreased by -0.14% in the last trading session.
Does PHATHOM PHARMACEUTICALS INC pay dividends?
PHAT does not pay a dividend.
How is the ChartMill rating for PHATHOM PHARMACEUTICALS INC?
PHAT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of PHATHOM PHARMACEUTICALS INC (PHAT) based on its PE ratio?
PHATHOM PHARMACEUTICALS INC (PHAT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.06).
Can you provide the market cap for PHATHOM PHARMACEUTICALS INC?
PHATHOM PHARMACEUTICALS INC (PHAT) has a market capitalization of 815.97M USD. This makes PHAT a Small Cap stock.
Can you provide the upcoming earnings date for PHATHOM PHARMACEUTICALS INC?
PHATHOM PHARMACEUTICALS INC (PHAT) will report earnings on 2026-04-29.